Want to see TSE:BNXT full AI Analyst Report?
BNXT Stock Chart & Stats
C$0.64
-C$0.02(-3.85%)
At close: 4:00 PM EST
C$0.64
-C$0.02(-3.85%)
Day’s Range― - ―
52-Week RangeC$0.32 - C$1.10
Previous CloseN/A
Volume110.36K
Average Volume (3M)80.86K
Market Cap
C$44.20M
Enterprise ValueC$54.38M
Total Cash (Recent Filing)C$12.07K
Total Debt (Recent Filing)C$6.30M
Price to Earnings (P/E)―
Beta0.29
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding129,994,550
10 Day Avg. Volume59,081
30 Day Avg. Volume80,860
Financial Highlights & Ratios
PEG Ratio-0.43
Price to Book (P/B)-8.07
Price to Sales (P/S)0.00
P/FCF Ratio-14.55
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Platform Licensing ModelA platform approach focused on reformulating existing active pharmaceutical ingredients creates a lower-risk path to commercialization: it can shorten development timelines, enable partnering/licensing deals, and scale revenue without the full capital intensity of novel drug R&D, supporting durable monetization if partnerships are secured.
Patient-friendly Dosage FocusConcentrating on oral thin films and other patient-friendly formats targets a lasting structural theme: improved adherence and differentiated dosing formats are increasingly valued by pharma and patients. That persistent demand can sustain licensing interest and steady product-market fit across therapeutic areas.
Improving Cash-burn TrendWhile still negative, a demonstrable reduction in cash burn versus earlier years shows management has taken steps to rein in costs and extend runway. Sustained operational discipline can materially reduce financing frequency and support execution on partnerships or focused product milestones over the coming months.
Bears Say
No Meaningful Revenue / CommercializationRevenue at effectively zero removes internal proof points for commercial adoption and severely limits the firm's ability to absorb fixed costs or negotiate favorable licensing terms. Without demonstrable sales, the business relies on future partnerships or financing to validate its delivery formats, increasing execution risk.
Weak Balance Sheet / Negative EquityNegative equity alongside meaningful debt constrains financial flexibility: it raises the probability of dilution or recapitalization, impedes access to debt markets on favorable terms, and reduces the ability to fund development internally. This structural weakness elevates financing and solvency risk.
Persistent Cash Burn Requiring FinancingOngoing negative free cash flow necessitates repeated external financing, which likely leads to dilution and can divert management attention. Dependence on outside capital makes strategic planning vulnerable to market conditions and limits the company's ability to invest selectively in commercial execution or scaling.
BioNxt Solutions News
BNXT FAQ
What was BioNxt Solutions’s price range in the past 12 months?
BioNxt Solutions lowest stock price was C$0.32 and its highest was C$1.10 in the past 12 months.
What is BioNxt Solutions’s market cap?
BioNxt Solutions’s market cap is C$44.20M.
When is BioNxt Solutions’s upcoming earnings report date?
BioNxt Solutions’s upcoming earnings report date is Aug 31, 2026 which is in 61 days.
How were BioNxt Solutions’s earnings last quarter?
Currently, no data Available
Is BioNxt Solutions overvalued?
According to Wall Street analysts BioNxt Solutions’s price is currently Overvalued.
Does BioNxt Solutions pay dividends?
BioNxt Solutions does not currently pay dividends.
What is BioNxt Solutions’s EPS estimate?
BioNxt Solutions’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BioNxt Solutions have?
BioNxt Solutions has 129,994,550 shares outstanding.
What happened to BioNxt Solutions’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of BioNxt Solutions?
Currently, no hedge funds are holding shares in TSE:BNXT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BioNxt Solutions
Headquartered in Vancouver, Canada, BioNxt Solutions Inc., established in 2017, operates as a bioscience company across Germany, Switzerland, Austria, Israel, and its home country. The firm focuses on developing innovative drug delivery systems, including transdermal patches and oral dissolvable films, specifically for neurological medications. It also advances psychedelic medicine applications to treat various mental health conditions such as depression, anxiety, addiction, and trauma-related stress disorder. Furthermore, BioNxt is engaged in creating point-of-care diagnostics, comprising rapid tests and biosensor screening tools, aimed at early disease detection, improved treatment efficacy, and enhanced disease management. This diagnostic portfolio features a COVID-19 PCR kit, alongside oral biosensors for peri-implantitis, H1N1 (swine flu), and H5N1 (avian flu). Complementing its development efforts, the company provides analytical testing and consulting services, and is involved in pathogen and oral health diagnostics, thin film drug formulation, and the production and formulation of psychedelic pharmaceuticals. The company adopted its current name in November 2022, having previously been known as XPhyto Therapeutics Corp.
Technical Analysis
Willow Biosciences Inc
―
Quantum Biopharma
―
MediPharm Labs
―
Avicanna
―
InnoCan Pharma
―
Options Prices
Currently, No data available
---